Showing papers by "Martine Extermann published in 2016"
University of North Carolina at Chapel Hill1, Thomas Jefferson University2, University of Rochester3, University of California, San Francisco4, Yale University5, American Society of Clinical Oncology6, Duke University7, City of Hope National Medical Center8, University of Texas Health Science Center at Houston9
TL;DR: The relevance of comorbidities in cancer is discussed, the commonly used tools to measure Comorbidity are examined, and the future direction of comorebidity research is discussed.
187 citations
TL;DR: Identified knowledge gaps in GA with management studies for older patients with cancer are summarized, proposed areas for future research are proposed and areas for research priorities are proposed.
94 citations
University of Rochester1, City of Hope National Medical Center2, Duke University3, National Institutes of Health4, Patient-Centered Outcomes Research Institute5, University of North Carolina at Chapel Hill6, University of Texas MD Anderson Cancer Center7, United States Public Health Service8, University of Alabama at Birmingham9, Beth Israel Deaconess Medical Center10, University of Chicago11
TL;DR: It was concluded that future intervention trials for older adults with cancer should rigorously test interventions to prevent the decline of or improve health status, especially interventions focused on optimizing physical performance, nutritional status, and cognition while undergoing cancer treatment.
Abstract: In May 2015, the Cancer and Aging Research Group, in collaboration with the National Cancer Institute and the National Institute on Aging through a U13 grant, convened a conference to identify research priorities to help design and implement intervention studies to improve the quality of life and survivorship of older, frailer adults with cancer. Conference attendees included researchers with multidisciplinary expertise and advocates. It was concluded that future intervention trials for older adults with cancer should: 1) rigorously test interventions to prevent the decline of or improve health status, especially interventions focused on optimizing physical performance, nutritional status, and cognition while undergoing cancer treatment; 2) use standardized care plans based on geriatric assessment findings to guide targeted interventions; and 3) incorporate the principles of geriatrics into survivorship care plans. Also highlighted was the need to integrate the expertise of interdisciplinary team members into geriatric oncology research, improve funding mechanisms to support geriatric oncology research, and disseminate high-impact results to the research and clinical community. In conjunction with the 2 prior U13 meetings, this conference provided the framework for future research to improve the evidence base for the clinical care of older adults with cancer. Cancer 2016;122:2459-68. © 2016 American Cancer Society.
91 citations
University of Tennessee Health Science Center1, University of Michigan2, Fox Chase Cancer Center3, University of California, San Diego4, Johns Hopkins University5, City of Hope National Medical Center6, Duke University7, University of Colorado Boulder8, University of Texas MD Anderson Cancer Center9, University of Nebraska Medical Center10, Yale Cancer Center11, Mayo Clinic12, Brigham and Women's Hospital13, Memorial Sloan Kettering Cancer Center14, Northwestern University15, Stanford University16, Ohio State University17, Roswell Park Cancer Institute18, University of California, San Francisco19, University of Utah20, Case Western Reserve University21, Seattle Cancer Care Alliance22, University of Washington23, National Comprehensive Cancer Network24
TL;DR: The NCCN Guidelines for Older Adult Oncology as discussed by the authors focused on the recent updates to the 2016 guidelines specific to the use of RT in the management of older adults with cancer.
Abstract: Cancer is the leading cause of death in older adults aged 60 to 79 years. Older patients with good performance status are able to tolerate commonly used treatment modalities as well as younger patients, particularly when adequate supportive care is provided. For older patients who are able to tolerate curative treatment, options include surgery, radiation therapy (RT), chemotherapy, and targeted therapies. RT can be highly effective and well tolerated in carefully selected patients, and advanced age alone should not preclude the use of RT in older patients with cancer. Judicious application of advanced RT techniques that facilitate normal tissue sparing and reduce RT doses to organs at risk are important for all patients, and may help to assuage concerns about the risks of RT in older adults. These NCCN Guidelines Insights focus on the recent updates to the 2016 NCCN Guidelines for Older Adult Oncology specific to the use of RT in the management of older adults with cancer.
78 citations
TL;DR: The analysis indicates that not offering treatment to patients older than 70 with AML is never acceptable and the optimum decision is driven by the patients9 preferences and estimated survival.
1 citations